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Background: Patients with low HDL cholesterol (HDLc) are at increased risk for atheroclerosis, and may benefit from combination therapy to 
raise HDLc. Fibrates may raise apolipoprotein A-I (apoAI) and HDLc modestly. Since niacin monotherapy raises apoAI robustly, we hypothesized that 
adding niacin to a fibrate would further augment the apoAI pool, thereby raising HDLc.
Methods: We standardized 11 men and 10 women with low HDLc to low-dose atorvastatin (Atv) 10 mg for 4 weeks and measured baseline lipids 
and apolipoprotein kinetics using a primed constant infusion of deuterated leucine. Subjects remained on Atv and added the novel fibrate fenofibric 
acid (FA, aka Trilipix) 135mg for 8 weeks, and then added extended-release niacin (NA), titrating to 2 g over 4 weeks, and continued triple therapy 
with Atv+FA+NA for an additional 6 weeks. Results are in mg/dL as mean (95% confidence interval).
Results: Baseline apoAI was 121 (112-130) on Atv and remained 119 (110-128) on adding FA (p=ns), and 116 (107-125) on adding NA (p=ns). 
Kinetic analysis showed no significant changes in apoA-I production or clearance. In contrast, HDLc rose from 35 (31-38) to 37 (34-40) on adding 
FA to Atv (p=0.03), and again to 40 (37-43) on Atv+FA+NA (p<0.0005), and the mean increase in HDLc on triple therapy was +18%.
Apolipoprotein B100 was 77 (68-85) on Atv and was similar on Atv+FA at 74 (66-83, p=ns), whereas adding NA lowered it to 63 (54-71, p<0.0005). 
Triglycerides dropped from 185 (125-245) on Atv to 119 (57-181) on Atv+FA (p=0.04), and again to 94 (29-160) on Atv+FA+NA (p=0.006). LDLc 
was stable in men, but dropped significantly in women (p=0.03 for gender interaction), who stayed between 92 (79-105) on Atv and 89 (76-103) on 
Atv+FA (p=ns), but dropped to 67 (52-81) on Atv+FA+NA (p=0.007). Dual therapy with Atv+FA and triple therapy with Atv+FA+NA were safe and well-
tolerated.
Conclusions: Surprisingly, on a background of low-dose atorvastatin neither the novel fibrate nor niacin improved apoAI levels or kinetics. In 
spite of this, HDLc rose significantly with addition of each drug, indicating that the change in HDLc was through a mechanism other than apoAI 
upregulation.
